Lexeo Therapeutics
https://www.lexeotx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Lexeo Therapeutics
Cautious Optimism Greets Lexeo’s LX2006 For Friedreich’s Ataxia
The company’s shares fell amid debate over improvements in LVMI, but an analyst pointed out that they indicated the gene therapy has efficacy in Friedreich ataxia cardiomyopathy.
Deal Watch: Bristol Adds To Vaccines ‘Repertoire,’ Takes ‘Scenic’ View Of Cellular Pathways
BMS partners with Repertoire and Scenic, plus deals involving: G1/Pepper, Harmony/Epygenix, Biodexa/Emtora, Regeneron/Mammoth, Vertex/Treefrog and Immedica/KKR/Impilo.
CGT Is In Its Infancy For CNS Disorders, But Technical Strides Being Made
Technical challenges and lackluster investor sentiment about the near-term commercial potential of cell and gene therapies in neurological disorders may be holding the field back.
Finance Watch: The Biggest Biopharma IPO Of 2024 May Not Happen In The US
Public Company Edition: Galderma proposed pricing for its $2.6bn Swiss public market debut. Also, Apogee and Akero lead follow-on offerings with $483m and $366.9m, respectively, and Lexicon’s private placement brings in $250m, while Spruce reveals a 21% workforce reduction.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
-
- Stelios Therapeutics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice